PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,300,746 | +15.8% | 83,300 | -3.6% | 0.05% | +25.0% |
| Q1 2023 | $1,987,200 | +333.9% | 86,400 | +49.2% | 0.04% | +233.3% |
| Q2 2022 | $458,000 | -88.8% | 57,923 | -66.5% | 0.01% | -87.4% |
| Q1 2022 | $4,095,000 | +808.0% | 172,941 | +1210.2% | 0.10% | +763.6% |
| Q4 2021 | $451,000 | +176.7% | 13,200 | -42.7% | 0.01% | -21.4% |
| Q1 2020 | $163,000 | +79.1% | 23,039 | +78.7% | 0.01% | +75.0% |
| Q4 2019 | $91,000 | -84.5% | 12,893 | -73.7% | 0.01% | -85.2% |
| Q3 2019 | $588,000 | -54.2% | 48,972 | -53.8% | 0.05% | -53.8% |
| Q2 2019 | $1,283,000 | +857.5% | 105,965 | +432.0% | 0.12% | +485.0% |
| Q4 2018 | $134,000 | – | 19,917 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |